Fagron announced that it entered into an agreement to acquire University Compounding Pharmacy. The enterprise value of the acquisition is $41.5 million.
University Compounding Pharmacy is a 503A pharmaceutical compounder specializing in the health and wellness segment, with strong positions in hormones and urology and a solid compliance record. It is based in San Diego, California.
Fagron is a leading global company active in pharmaceutical compounding, focusing on delivering personalized medicine to hospitals, pharmacies, clinics and patients in 35 countries around the world. Fagron’s operational activities are managed by the Dutch company Fagron BV, which is headquartered in Rotterdam.
The acquisition deepens Fagron’s presence in North America’s prevention and lifestyle segment and strengthens its position in California. The deal will be fully financed through Fagron’s own resources and remains subject to customary clearance.
According to data in the LevinPro HC database, this transaction represents the 19th Specialty Pharmacy transaction of the year; in 2024, 28 were reported.
